Organization
Department of Experimental Therapeutics, National Cancer Center Hospital East
8 abstracts
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Washington University School of Medicine, Department of Immunology and Oncology, Clínica Universidad de Navarra, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
A mobile app–based program for facilitating advance care planning discussions between patients with advanced cancer and oncologists: A randomized controlled trial (J-SUPPORT 2104).Org: Institute for Cancer Control, National Cancer Center Hospital East, Kashiwa, Japan, Division of Survivorship Research, Division of Behavioral Sciences, Japanese Organisation for Research and Treatment of Cancer,
Abstract
Insights from C-CAT repository: A novel approach to identifying appropriate patient populations for anticancer drug development using the clinicogenomic nationwide database in Japan.Org: National Cancer Center Research Institute, National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East,
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology,
Abstract
Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.Org: START Midwest, Grand Rapids, MI, National Cancer Center Hospital East, Kashiwa, Japan, University of Colorado Cancer Center, Rambam Medical Center, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Impact of patient travel time on disparities in precision oncology clinical trials.Org: Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Tokyo, Japan,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,